Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Analysts, who are highly bullish on the stock, have fretted for some time that Viking needed a partner to actually make the ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics. The two companies will work together to ensure the production of Viking’s GLP ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...